Pam Morley to Serve as Fluidigm Vice President, Sales, Service, and Support for North America.

SOUTH SAN FRANCISCO, Calif. -- Pam Morley, Ph.D., has joined Fluidigm Corporation as the Vice President, North American Sales, Service, and Support. Dr. Morley brings to Fluidigm more than twenty years of experience in sales, management, and customer service and support, in the life science tools business. She has demonstrated success in introducing and building distribution channels for highly innovative technologies, spanning a broad range of customer applications in protein chemistry and molecular biology.

"Pam's background is well aligned with our strategy to revolutionize life-science efficiencies through our integrated fluidic circuits. Her ability to rapidly grow revenues with breakthrough products and her depth of experience with service and support organizations will be an asset to both our company and our customers," said Fluidigm CEO Gajus Worthington.

Over the past two decades Dr. Morley has held positions of increasing responsibility at Applied Biosystems (ABI). From 1984 - 1997 she held various sales and district manager titles covering mainstay product categories, such as automated DNA synthesis, fluorescent DNA sequencing, and real-time quantitative PCR. From 1998 - 2002 she served as a regional sales manager, when the company experienced exponential growth in revenues from its genomics technology. From 2002 until recently she was a director of service for the molecular biology and the proteomics and mass spec product lines.

Dr. Morley joins Fluidigm as it introduces an automated system targeted to a high-growth sector, biomarker validation. The system includes nanofluidic chips and instrumentation for real-time qPCR and radically improves throughput and ease of use for a range of genomic applications. The system will be officially launched at a special event on October 23, at Cambridge Health Technology conference Discovery on Target. The BioMark system epitomizes the Fluidigm strategy of marrying the company's breakthrough nanofluidic chips with gold standard biochemistries.

Dr. Morley earned her Ph.D. in physical chemistry and completed a post doc at the University of Virginia. Her research resulted in six peer reviewed publications.

About Fluidigm

Fluidigm Corporation develops and distributes systems based on the unique properties of integrated fluidic circuits (IFCs) to precisely control fluids on a nanovolume scale. The company's vision is to create and to lead a new industry in which IFCs bring unparalleled efficiencies to the life science and allied fields. Based in South San Francisco, California, the Company is privately held and backed by premier investors: Versant Ventures, Euclid SR Partners, InterWest Partners, Alloy Ventures, Lehman Brothers Healthcare Fund, the Singapore EDB, Bruce Burrows, Lilly BioVentures, the Invus Group, SightLine Partners, AllianceBernstein and GE Equity.